Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

This study has been completed.
Sponsor:
Collaborator:
University of California, San Francisco
Information provided by (Responsible Party):
Nancy E. Lane, MD, University of California, Davis
ClinicalTrials.gov Identifier:
NCT00221299
First received: September 14, 2005
Last updated: November 26, 2012
Last verified: November 2012
  Purpose

The purpose of the study is to learn if one year of treatment with parathyroid hormone (PTH), either alone or with risedronate, will increase the thickness of the bones in the hip and spine in subjects with osteoporosis from chronic low dose steroid use. During the second year, the study will also look at whether taking risedronate will preserve the bone thickness created by one year of rhPTH 1-34 treatment.


Condition Intervention Phase
Glucocorticoid Induced Osteoporosis
Drug: Risedronate
Drug: Parathyroid Hormone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Can Risedronate and Parathyroid Hormone Reverse Glucocorticoid Induced Osteoporosis?

Resource links provided by NLM:


Further study details as provided by University of California, Davis:

Primary Outcome Measures:
  • Bone Mineral Density (BMD): Examine the pattern and effect of BMD changes at hip and spine measured by DXA every 6 months. [ Time Frame: BMD changes from year 1 to year 2 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Bone Turnover Markers : Evaluate the levels of bone biochemical markers serum total calcium and urinary excretion of calcium. [ Time Frame: end of year 2 ] [ Designated as safety issue: No ]
  • Incident Vertebral and non-Vertebral Fractures: Evaluate using Instant Vertebral Assessment (IVA) obtained at baseline and annually thereafter. [ Time Frame: compare end of year 1 and end of year 2 ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: September 2005
Study Completion Date: May 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
parathyroid hormone (rhPTH 1-34) injections and risedronate placebo tablets for one year
Drug: Parathyroid Hormone
This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
Other Names:
  • Forteo
  • PTH
  • rhPTH 1-34
  • NDC# 0002-8971-01
Active Comparator: 2
Parathyroid hormone (rhPTH 1-34) injections and risedronate tablets for one year
Drug: Risedronate
One 35mg tab of risedronate/placebo taken once a week for one year.
Other Name: Actonel, NDC# 0149-0472-04
Drug: Parathyroid Hormone
This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
Other Names:
  • Forteo
  • PTH
  • rhPTH 1-34
  • NDC# 0002-8971-01
Active Comparator: 3
parathyroid hormone (rhPTH 1-34) placebo injections and risedronate tablets for one year
Drug: Risedronate
One 35mg tab of risedronate/placebo taken once a week for one year.
Other Name: Actonel, NDC# 0149-0472-04

Detailed Description:

Dr. Nancy Lane and colleagues at the University of California, Davis and University of California, San Francisco will be conducting this 2-year study of human parathyroid hormone (rhPTH 1-34) alone, and rhPTH (1-34) with risedronate compared to risedronate alone in men and women with osteopenia on chronic low dose glucocorticoids (GC). This is an investigator-initiated study funded by Aventis Pharmaceuticals.

The study will be divided into 2 phases. All study subjects will receive supplemental calcium citrate and Vitamin D during the 2-year study. In year one subjects will be randomly assigned to receive PTH (subcutaneously daily) or placebo and risedronate tablets or placebo. In year two, PTH will be stopped and subjects will be re-randomized to receive risedronate tablets or placebo.

Potential study subjects will have dual x-ray absorptiometry measurements (DEXA) of the spine and hip at the screening visit. Those study subjects who meet the inclusion criteria will be invited back for a baseline visit.

DEXA scans of the spine, hip, and forearm will be done at Baseline visit, 6-month, 12-month, 18-month, and 24-month follow-up visits. DEXA scan of the spine, hip, and forearm takes approximately 20 minutes to complete. To assess incident vertebral and non-vertebral fractures, lateral thoracic and lumbar spine evaluation using Instant Vertebral Assessment [IVA] will be done at Baseline, 12-month, and 24-month follow-up visits.

The specific aims of the study are as follows:

  1. To determine if changes in bone mineral density in the spine and hip caused by 1 year of treatment with rhPTH (1-34) alone then followed by risedronate or rhPTH (1-34) with risedronate are greater than PTH placebo and risedronate in patients with GIO who are taking calcium, MVIs and chronic low doses of glucocorticoids.
  2. To determine if risedronate will preserve the high bone mass state created by 1 year of rhPTH (1-34) treatment.
  3. To determine the association of biochemical markers of bone turnover with rhPTH (1-34) and risedronate both during and after treatment.
  4. To compare, as possible, the fracture incidence between the rhPTH (1-34) alone followed by risedronate, and rhPTH (1-34) with risedronate compared to risedronate + placebo groups.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women, greater than 18 years of age with a history of glucocorticoid therapy with prednisone ≥ 7.5mg/d for 6 months, and currently on prednisone ≥ 5mg /day.
  • DXA of the lumbar spine (L1-L4) or total hip or femoral neck T score ≤ -1.5 with or without a prevalent vertebral fracture. (The T score is the number of standard deviations above or below the population mean for young, normal pre-menopausal females age 30).
  • Investigators are satisfied that that there is no physical condition that would prevent a patient from receiving the proposed treatment regimens.
  • Patient is ambulatory and able to return to the site of the investigation at specified time during the study.
  • The patient is willing to participate in the proposed study as evidenced by signing an informed consent.
  • Women of childbearing age are willing to use 2 forms of contraception during the entire study period.
  • Have at least one analyzable BMD site: lumbar spine and/or proximal femur

Exclusion Criteria:

  • Generalized disease of bone other than related to a rheumatic disease and glucocorticoid-induced osteoporosis including: hyperparathyroidism, hypoparathyroidism, Paget's disease of bone
  • Diseases that may affect bone metabolism including: alcoholism, hyperthyroidism, renal impairment (creatinine > 2.5mg/dl) or hepatic impairment (SGOT levels > 2x upper limit of normal
  • Urinary excretion of calcium > 400mg/day
  • History of drug abuse
  • Previous use of alendronate within 6 months prior to the study
  • Previous use of risedronate, hormone replacement therapy or calcitonin within 2 months prior to the study
  • History of unstable cardiovascular disease or uncontrolled hypertension
  • Severe scoliosis, greater than 2 lumbar fractures, or spinal surgery such that a precise bone mass measurement could be affected
  • History of gastrointestinal intolerance to bisphosphonates
  • History of cancer within 5 years of the study
  • Patients on glucocorticoids for organ transplantation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00221299

Locations
United States, California
UC Davis General Medicine Research Clinic
Sacramento, California, United States, 95817
Sponsors and Collaborators
University of California, Davis
University of California, San Francisco
Investigators
Principal Investigator: Nancy E Lane, MD University of California, Davis
  More Information

No publications provided

Responsible Party: Nancy E. Lane, MD, Principal Investigator, University of California, Davis
ClinicalTrials.gov Identifier: NCT00221299     History of Changes
Other Study ID Numbers: 200513216
Study First Received: September 14, 2005
Last Updated: November 26, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by University of California, Davis:
Osteoporosis
Steroids
Prednisone

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Hormones
Risedronic acid
Etidronic Acid
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Therapeutic Uses
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on September 18, 2014